Printer Friendly

CRYOLIFE, INC. GRANTED FDA APPROVAL TO EXPAND PROGRAM FOR HUMAN ALLOGRAFT HEART VALVES

 ATLANTA, June 10 /PRNewswire/ -- CryoLife, Inc. (NASDAQ-NMS: CRYL) has received approval from the FDA (Food and Drug Administration) on its request to expand its investigational device exemptions (IDE) for implantation of human heart valves.
 The expanded IDE study provides the company with up to 35 patient implants at each of the 10 primary medical centers and up to 1,200 patient implants at 440 secondary medical centers.
 According to Steven G. Anderson, president and chief executive officer of CryoLife, Inc.: "The expansion of our IDE allows the company to continue providing human heart valves (CryoValve) to meet demands from the medical community and implanting physicians. Availability and access to allograft heart valves is considered essential by many cardiovascular surgeons for treatment of heart patients for whom mechanical heart valves would be an unsatisfactory substitute."
 Allograft heart valves have become an increasingly important heart valve replacement alternative for children with congenital cardiac anomalies and women of child-bearing age. Through 1992, over 900 physicians have implanted more than 13,000 CryoLife preserved valves at medical centers throughout the United States.
 CryoLife, Inc. anticipates submitting its premarket approval (PMA) application to the FDA for CryoValve in the near future.
 Founded in 1984, CryoLife, Inc. is a leader in the development and commercialization of technology for ultra-low temperature preservation ("cryopreservation") of viable human cardiovascular and orthopaedic tissues for transplant. The company uses proprietary or patented processes to disinfect, preserve, store and transport human heart valves, veins and connective tissues for use in cardiac, vascular and orthopaedic surgeries.
 The company is also the exclusive worldwide distributor for Bravo Cardiovascular, Inc., implantable porcine (pig) cardiovascular devices.
 -0- 6/10/93
 /CONTACT: Suzanne Gabbert, assistant corporate secretary of CryoLife, 800-438-8285/
 (CRYL)


CO: CryoLife, Inc. ST: Georgia IN: MTC SU:

BN-TG -- AT003 -- 0493 06/10/93 09:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:301
Previous Article:ELECTRONIC ARTS HONORED BY STANFORD BUSINESS SCHOOL ALUMNI AS 1993 ENTREPRENEURIAL COMPANY OF THE YEAR
Next Article:HOECHST CELANESE SUSPENDING OPERATION OF BOTTLE RECYCLING FACILITY WHILE CONTINUING TO EXPAND ENCORE RESINS CAPABILITY
Topics:


Related Articles
CRYOLIFE, INC. SUBMITS PREMARKET APPROVAL (PMA) APPLICATION TO FDA ON CRYOPRESERVED HEART VALVES
CRYOLIFE, INC. GRANTED FDA APPROVAL TO EXPAND IMPLANT PROGRAM FOR HUMAN ALLOGRAFT HEART VALVES
CRYOLIFE, INC. REPORTS RECORD YEAR END REVENUES
CRYOLIFE, INC. TO ACQUIRE CAMBRIDGE BIOMEDICAL, LTD.
CRYOLIFE, INC. TO ACQUIRE CAMBRIDGE BIOMEDICAL, LTD.
CRYOLIFE, INC. ADDS STENTLESS PORCINE HEART VALVE TO CORE BUSINESS
CRYOLIFE, INC. RECEIVED 'CE' MARK PERMITTING EUROPEAN DISTRIBUTION OF PORCINE HEART VALVES
CryoLife Inc. Receives Grant For Development of Bioengineered Tissue Heart Valve
CryoLife, Inc. Receives Major Grant For The Development of Bioengineered Heart Valves
CryoLife, Inc. Awarded CE Mark for CryoLife-Ross Pulmonary Stentless Porcine Heart Valve

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters